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Abstract
Introduction: Neonatal Abstinence Syndrome (NAS) is a collection of withdrawal symptoms
following the abrupt discontinuation of a substance exposed to during pregnancy. East Tennessee
Children’s Hospital (ETCH) has altered their treatment protocol in attempt to decrease the length
of stay (LOS) for their NAS patients. The purpose of this study was to compare the NICU LOS
for NAS treated infants prior to and after implementation of a standardized treatment protocol
that includes Rescue Dosing. Despite thorough research related to effective treatment, a
consistent protocol has not been identified. It is unclear if a strict standardized treatment protocol
can decrease the LOS for these infants.
Methods: ETCH introduced their current protocol in July 2014. A retrospective chart review
was performed to collect data on the pharmacological treatment, LOS, and select demographic
characteristics. Differences in LOS were analyzed using an independent t-test to determine if
there was a significant difference in LOS pre- and post-protocol implementation.
Analysis: A total of 1,022 neonatal charts were reviewed. The average LOS for 345 neonates
prior to initiation of the Rescue Dosing protocol was 23.9 days. After the introduction of the new
standardized treatment protocol, the average LOS for 677 neonates decreased to 17.5 days. This
was a statistically significant difference of 6.4 days. There was a significant decrease in NICU
LOS after implementation of the new treatment protocol including Rescue Dosing and validates
the use of Rescue Dosing.
Conclusion: Rescue Dosing as an intervention was found to be effective in reducing LOS, with a
resultant reduction in hospital-related costs. It is recommended to utilize a standardized treatment
protocol including Rescue Dosing in the treatment of NAS.
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Rescue Dosing as a Standardized Treatment Protocol for Neonatal Abstinence Syndrome to
Decrease Length of Hospital Stay
Introduction
Neonatal Abstinence Syndrome (NAS) is a compilation of withdrawal symptoms
experienced by newborns following the abrupt discontinuation of a substance the fetus was
exposed to during pregnancy. According to Wachman & Schiff (2016), NAS accounts for nearly
3% of all admissions into the Neonatal Intensive Care Unit (NICU) coupled with costs of around
$50,000 per admission.
In patients diagnosed with NAS, medications are used to control the signs and symptoms
of withdrawal and to avoid complications such as seizures. It is vital to determine the need for
pharmacological interventions promptly after diagnosis to decrease LOS and risk for fatality.
Although the implementation of non-pharmacological interventions, and, later, pharmacological
interventions have been shown to be effective for the treatment of NAS, there are many
researchers who are finding that integrating these practices at varying points in the treatment
process may not be the best option for every neonate with a NAS diagnosis. While many NICUs
seem to be utilizing the same medications for minimizing the withdrawal symptoms, most lack a
standardized approach to weaning which often leads to longer, more expensive stays in the
NICU.
Each neonate exhibits the signs and symptoms of NAS and responds to treatments
differently. However, recent studies have shown that a strict, standardized treatment protocol can
minimize variance and improve communication among caregivers leading to an overall reduction
in the LOS.
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To decrease the NICU LOS for neonates diagnosed with NAS, East Tennessee Children’s
Hospital (ETCH) implemented a new treatment protocol with Rescue Dosing. Typically, a
treatment protocol follows a specific pattern of taking a Finnegan score and medicating based on
that score with no room for compensation. So, if the dose was not strong enough to decrease the
Finnegan score effectively, the treatment regimen could be restarted leading to an increased
LOS. Rescue Dosing is an additional dose of morphine on top of the scheduled dose which is
ordered when the symptoms are not able to be managed at the current level. This protocol allows
the patient to wean off morphine treatment at a steady rate without the possibility of needing to
start the medication regimen process over. The purpose of this study is to evaluate the
effectiveness of this treatment protocol in decreasing the NICU LOS in infants treated for NAS
at ETCH. It is hypothesized that NAS infants treated with rescue dosing will have shorter LOS’s
than those that do not receive rescue dosing.
Review of Literature
PubMed was utilized to find sources pertaining to the treatment of NAS. Key words used
were “Neonatal Abstinence Syndrome,” “treatment,” “protocol,” and “weaning.” After
narrowing the results to include only sources within the last five years, 40 sources were
reviewed. There were 13 sources found relevant to this study. The sources were excluded if they
were outside of the United States or focused on non-pharmacological interventions. There were
seven cohort studies, two randomized control trials, and four retrospective chart reviews. These
sources were divided into pharmacological interventions and standardized treatment protocols.
Currently, there are a multitude of medications administered to wean NAS infants off
narcotics including morphine, methadone, phenobarbital, buprenorphine, and clonidine. These
medications differ in the symptoms treated, frequency and strength of dosing, long-term effects,
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and their half-life. Morphine is often preferred due to how quickly and effectively it works
although it requires many doses in a short amount of time and can prolong an infant’s LOS.
However, a standard plan of care was not found in the literature for the treatment of NAS infants.
Morphine versus Methadone
DeAtley, Burton, Fraley, & Haltom (2017) evaluated the effects of two different
morphine treatment protocols. The only difference between the two protocols was the initial
amount of morphine given. It was higher by 0.02 mg/kg/dose in the second protocol. There were
58 neonates with 33 receiving the first protocol and 26 receiving the second protocol. They
found that the increased morphine dose reduced the LOS and duration of opioid exposure by
seven days. However, they discovered a need for more studies using different amounts of
morphine to determine the best initial dose because higher starting doses of morphine have been
linked to an increased risk of over sedation which could jeopardize the treatment of an infant
with NAS.
Burke and Beckwith (2017) followed 36 neonates suffering from NAS that were treated
with either morphine or methadone to determine the impact these drugs had on their overall LOS
and their level of development following treatment. The 19 neonates that were treated with
morphine had a slightly shorter LOS than those treated with methadone as well as significantly
higher scores in cognitive and gross motor areas of the Bayley Scales of Infant and Toddler
Development. None of these results were statistically significant. This study was limited by the
small sample size. However, they concluded that morphine would be the best choice for
treatment based on the differences in LOS. Although infants receiving methadone treatment had
a longer LOS, it was administered less frequently. The researchers determined that this was a
benefit to the methadone treatment.
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Brown, Hayes, & Thornton (2015) implemented a randomized control trial that included
31 neonates diagnosed with NAS to compare the duration of treatment for morphine therapy and
methadone therapy. The duration of treatment was reported to be directly correlated to the LOS
because this sample did not have any unresolved medical conditions that would require them to
remain in the hospital after NAS treatment. The infants receiving methadone therapy had a
shorter duration of treatment by seven days which would lead to a shorter LOS than the
morphine therapy. They stated that the sample size in this study was a limitation and that it
should be performed with a larger sample size to determine the accuracy of the results.
Hall, Meinzen-Derr, & Wexelblatt (2015) conducted a study to evaluate two methadone
protocols and their effects on duration of treatment, overall LOS, and total amount of methadone
administered. The sample included 360 neonates with 267 neonates treated with the original
methadone protocol while 93 were treated with the newly revised methadone protocol. The
primary difference between the two protocols was the utilization of pharmacokinetic modeling in
the revised protocol. It was shown that the revised protocol resulted in a shorter duration of
treatment and LOS by three days. However, there was no difference in the amount of methadone
administered. They recommend refining a standardized methadone protocol to reduce LOS and
duration of treatment even further.
Each of these studies were conducted to compare methadone and morphine as well as
variations in either type of therapy. The results were conflicting so there is no evidence that
either medication or protocol is better suited for the treatment of NAS.
Adjunct Medications
While morphine and methadone are the medications of choice, other adjunct medications
can be incorporated into the protocol to avoid the possibility of overdosing. Phenobarbital is safe
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to use for treating seizures associated with NAS, but it presents the risk of interacting with the
opioids exposed to in utero. Clonidine is preferred for less sedation but can cause hypotension
and has negative effects when discontinued suddenly.
Devlin, Lau, & Radmacher (2017) performed a study between 2005 and 2015 at the
University of Louisville Hospital comparing the effects of two protocols. The protocols differed
in the adjunct medication being utilized, specifically phenobarbital and clonidine, alongside
differing doses of morphine. The sample consisted of 190 neonates assigned to two different
groups. The results showed that using morphine every three hours with clonidine as a
supplemental therapy decreased the length of morphine therapy by 8.5 days, the need for adjunct
therapy by 24%, and the overall LOS by nine days. They also evaluated the cost reduction
associated with the decreased LOS to $27,000 per patient in savings. They recommend the use of
more intense morphine weaning to optimize the outcomes of treatment.
Buprenorphine administered sublingually is another medication used in NAS treatment.
Kraft et al. (2017) performed a double-blind clinical trial to compare the treatment effects of
morphine and buprenorphine with supplemental phenobarbital for uncontrolled symptoms. There
were 33 neonates who received buprenorphine therapy and 30 neonates who received morphine
therapy. Outcome variables included the duration of treatment, overall LOS, and the percentage
of adjunct treatment. They found a shorter duration of treatment by 13 days and a shorter LOS by
12 days in the neonates treated with buprenorphine therapy. Adjunct phenobarbital was needed
for five neonates in the buprenorphine therapy group and seven neonates in the morphine therapy
group. The researchers stated that these findings suggest that buprenorphine could possibly be
more effective than morphine. However, both medications continued to show the same adverse
effects and the sample size was relatively small.
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Hall et al. (2016) compared 38 neonates receiving sublingual buprenorphine therapy to
163 neonates receiving oral methadone therapy (n = 163) to determine if one protocol was more
effective in decreasing the LOS. The neonates that received buprenorphine therapy had a shorter
treatment duration by five days and a four day shorter LOS. The unequal group sizes were a
limitation of the study as well as the different routes for the medications. However, the
researchers suggest that, based on their findings, sublingual buprenorphine therapy may be better
suited for select neonates.
These trials and studies suggest the need for further research into stringent protocol-based
weaning rather than the logistics behind which medications individually reduce LOS and adverse
effects. Each medication has specific strengths and weaknesses as well as a certain dependence
on the circumstances of each neonate. Therefore, the type of medication only plays a part in the
overall determination of effective treatment.
Standardized Treatment Protocols
Asti, Magers, Keels, Wispe, and McClead (2015) implemented a standardized morphine
protocol for 92 neonates with 23 used as the baseline. They found that the average LOS was
drastically reduced from 36 to 18 days. There were no readmissions after discharge for further
treatments or complications. They reported adverse patient harm, impaired maternal-infant
attachment, and significant health care costs were associated with prolonged LOS.
Similar results were found by Burnette, Chernicky, and Towers (2018). Their study
included 395 neonates with 233 treated before the implementation of a standardized morphine
weaning protocol and 162 treated with the new weaning protocol. The LOS was reduced from 23
days to 18 days in those neonates treated after the implementation of a strict standardized
morphine protocol. The researchers used these findings to suggest the need for more
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standardized protocol analysis at single sites. The limitation of this study was the sample
consisted of primarily Caucasian neonates.
Hall et al. (2015) compared the outcomes of six hospitals pre- and post- implementation
of a standardized protocol. The sample included 981 neonates. Each hospital compared its
previous measured the LOS’s for neonates, then a standardized treatment protocol was
implemented in three of the six hospitals. They also collected data on the duration of opioid
treatment using both protocols. The neonates in the three hospitals that utilized the standardized
protocol had an average of 8 day shorter LOS and an average 11-day shorter duration of opioid
treatment. A possible limitation of this study was the use of different medications at the
hospitals. However, they found that protocol-driven weaning may be more effective in
decreasing LOS and duration of opioid exposure than the actual type of medication.
Hall et al. (2014) examined the effectiveness of a new NAS weaning protocol. The
sample consisted of 547 neonates with 130 being in a control group and 417 being treated with a
new NAS weaning protocol. They evaluated the treatment duration and the overall LOS. The
neonates treated with the NAS weaning protocol showed a shorter duration of treatment by 15
days and a shorter LOS by 10 days. The hospital variation and the different medications used in
the control group were limitations of this study. The researchers recommended the use of a
stringent treatment protocol to treat infants with NAS.
Patrick, Kaplan, Passarella, Davis, & Lorch (2014) compared the effectiveness of
morphine, methadone and phenobarbital on duration of treatment, LOS and hospital charges. Six
hospitals used morphine, six hospitals used methadone, and the other two hospitals used
phenobarbital. The sample consisted of 1,424 neonates from 14 different hospitals They found
that the hospitals using methadone therapy had a decreased duration of treatment by five days
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and a decreased LOS by four days. However, there was no difference in hospital charges
between the hospitals using methadone and those using morphine. The use of phenobarbital was
associated with increased LOS, duration of treatment and hospital charges. After considering the
possibility of case-mix, the researchers determined the hospitals varied in these aspects.
Ultimately, they recommend the development of a standardized treatment protocol to improve
care, outcomes, and cost.
Saunders et al. (2014) at East Tennessee Children’s Hospital implemented an evidencebased NAS protocol to improve outcomes including LOS and post-wean stay. They conducted a
retrospective analysis of 386 neonates before and after implementation to compare the LOS and
post-wean stay. In those neonates treated after the implementation of the new protocol, the LOS
was reduced by 10.35 days and the post-wean stay was reduced by 2.79 days. They reported
rapid cycles of change during the implementation which created less control of confounding
variables. The researchers recommend using a multidisciplinary approach to improve efficiency
of weaning.
Each of these studies evaluated different medications and protocols to determine the
importance of the actual medication in the treatment of NAS. These studies did not result in a
clear recommendation for medication use. However, the use of a standardized protocol resulted
in significant changes in LOS, duration of treatment and hospital costs.
The purpose of this study was to determine the effect of including Rescue Dosing in the
standardized treatment protocol on neonatal outcomes treated for NAS. It was hypothesized that
neonates who received the Rescue Dosing treatment protocol would demonstrate a shorter LOS
and treatment duration than those treated with the prior treatment protocol at ETCH.
Methods
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A quasi-experimental design was used to determine the effectiveness of the change in
treatment protocol. Prior to July 2014, the treatment protocol used at ETCH did not include the
option of an additional high dose of morphine for weaning, known as Rescue Dosing. The
effectiveness of Rescue Dosing was determined by comparing the average LOS for patients
treated prior to and after the implementation of Rescue Dosing.
Sampling
Neonates were included if they met the inclusion criteria of a neonate treated at ETCH
for NAS from 2011 to 2018 with no additional medical condition. Any neonate with a post-wean
stay greater than five days was excluded due to the probability of complications leading to the
extended stay. This was a potential confounding factor that was accounted for prior to data
collection.
A sample size of 200 neonates with 100 in each group was determined with a power
analysis. The sample consisted of 1,022 neonates treated for NAS at ETCH from August 2011April 2018. There were 345 neonates treated without Rescue Dosing and 677 neonates with the
Rescue Dosing treatment protocol.
Data Collection and Measures
The data was collected from patient records by the IRB Specialist at ETCH and compiled
into an excel sheet. All data was downloaded without patient identification. The data collected
included diagnoses, age at admit, age at discharge, LOS post-wean, race, gestational age, body
weight, zip, substance exposure in utero, medications and dosages. There were no measures used
to confirm reliability of the data.
Analysis
Analysis was conducted using SPSS 19. A p-values of < .05 indicated significance.
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Sample Characteristics
The sample consisted of 1,022 neonates who were diagnosed with NAS and treated at
ETCH. There were 550 males (54%) and 470 females (46%) with 2 listed as unidentified. The
neonates were 87% Caucasian, 5% African American, and 8% other. The birth weight ranged
from 1220 grams to 4576 grams with a mean of 2989 grams. There were no significant
differences in the demographic characteristics between the two groups.
Research Variables
The LOS post-wean and LOS frequencies were calculated for the entire sample before
splitting the data into the two protocol groups. The number of days post-wean ranged from 0.4
days to 5 days with a mean of 3.8 days (sd = 0.39). The number of days for LOS ranged from 3
days to 56 days with a mean of 19.7 days (sd = 7).
Testing the Hypothesis
To determine if the LOS of neonates treated with rescue dosing was significantly less, s ttest calculated. There was statistically significant difference in the post-wean LOS between
neonates who did and did not receive Rescue Dosing (t = 6.15, df = 1020, p < .000). The
neonates in the group without Rescue Dosing had a longer post-wean (x = 3.5, sd = 0.39). then
the neonates who received Rescue Dosing (x = 3.3, sd = 0.37) However, these results do not
have clinical significance.
There was statistically significant difference in LOS between the neonates in the two
groups (t = 15.3, df = 1020, p < .000). The neonates in the group prior to Rescue Dosing had a
longer LOS (x = 23.9, sd = 7.7) compared to neonates who received Rescue Dosing (x = 17.5, sd
= 5.4). There was a difference of 6.4 days between the two groups.
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